In addition to recovery, they may enhance muscle growth
A meta-analysis of 6 studies 13,20,30,32,33,35 which attempted to estimate overall effect size of the changes from baseline in % FMD following GLP-1-based therapies could not find any significant difference between baseline and end-of-treatment samples (mean change from baseline was 0.83 [1.06, 2.73] %
There are three variables that govern how severe your die-off symptoms will be: How many bacteria are dying: The more bacteria, the bigger the burden your body has to manage
Am J Pathol 172(4):940950 Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014a) Tofacitinib versus methotrexate in rheumatoid arthritis